Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma



Summary

Plasmapheresis, a procedure that filters blood, has shown promise in overcoming resistance to anti-BCMA immunotherapies for multiple myeloma. These immunotherapies target BCMA, a protein on myeloma cells. However, some patients exhibit primary resistance, often due to high levels of soluble BCMA in their blood, which neutralizes the therapy. Studies suggest that plasmapheresis effectively removes this soluble BCMA, improving the efficacy of anti-BCMA immunotherapies. By clearing the soluble target, the therapy can more effectively bind to and eliminate myeloma cells, potentially reversing primary resistance and improving patient outcomes.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!